Cargando…

Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells

Acute promyelocytic leukemia (APL) is characterized by arrested differentiation of promyelocytes. Patients treated with all-trans retinoic acid (ATRA) alone experience relapse, while patients treated with ATRA and arsenic trioxide (ATO) are often relapse-free. This suggests sustained changes have be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huynh, Thomas T., Sultan, Mohammad, Vidovic, Dejan, Dean, Cheryl A., Cruickshank, Brianne M., Lee, Kristen, Loung, Chao-Yu, Holloway, Ryan W., Hoskin, David W., Waisman, David M., Weaver, Ian C. G., Marcato, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602962/ https://www.ncbi.nlm.nih.gov/pubmed/31263158 http://dx.doi.org/10.1038/s41598-019-45982-7

Ejemplares similares

Regulation of cell surface protease receptor S100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL)(☆)
por: Holloway, Ryan W., et al.
Publicado: (2018)

An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)
por: Wang, Huai-Yu, et al.
Publicado: (2022)

Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
por: Kayser, Sabine, et al.
Publicado: (2020)

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group
por: Adès, Lionel, et al.
Publicado: (2018)

Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
por: Kayser, Sabine, et al.
Publicado: (2021)

Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo
por: Atashrazm, Farzaneh, et al.
Publicado: (2016)

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives
por: McCulloch, Derek, et al.
Publicado: (2017)

ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells
por: Vidovic, Dejan, et al.
Publicado: (2019)

Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress
por: Masciarelli, S, et al.
Publicado: (2018)

All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis
por: Colvin, Teresa A., et al.
Publicado: (2018)

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives [Corrigendum]
Publicado: (2017)

Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study
por: Zheng, Huyong, et al.
Publicado: (2021)

Effects of arsenic trioxide, all-trans-retinoic acid and dexamethasone on NB4 cell line
por: Mandegary, A., et al.
Publicado: (2010)

Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia
por: Kulkarni, Uday P., et al.
Publicado: (2022)

Multicenter randomized trial of arsenic trioxide and Realgar‐Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG‐APL clinical study
por: Yang, Ming‐Hua, et al.
Publicado: (2018)

DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid
por: Coyle, Krysta Mila, et al.
Publicado: (2018)

Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all‐trans retinoic acid and arsenic trioxide
por: Habibi, Maryam, et al.
Publicado: (2021)

Acute Promyelocytic Leukemia and Brugada Syndrome: A Report on the Safety of Arsenic Trioxide/All-Trans-Retinoic Acid Therapy
por: Rosati, Giorgio, et al.
Publicado: (2023)

APL Congress
por: Gjerløv, Per, et al.
Publicado: (1973)

Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia in the Era of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO)
por: Colita, Andrei, et al.
Publicado: (2023)

APL : a short course
por: Pakin, Sandra
Publicado: (1973)

All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis
por: Ma, Yafang, et al.
Publicado: (2016)

Evidences of Protective Potentials of Microdoses of Ultra-High Diluted Arsenic Trioxide in Mice Receiving Repeated Injections of Arsenic Trioxide
por: Banerjee, Pathikrit, et al.
Publicado: (2011)

Budgetary Impact of Treating Acute Promyelocytic Leukemia Patients with First-Line Arsenic Trioxide and Retinoic Acid from an Italian Payer Perspective
por: Kruse, Morgan, et al.
Publicado: (2015)

Two cases of differentiation syndrome with ocular manifestations in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and arsenic trioxide
por: Newman, A.R., et al.
Publicado: (2018)

All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells
por: Liu, XiangZhen, et al.
Publicado: (2017)

In silico mechanisms of arsenic trioxide-induced cardiotoxicity
por: Li, Yacong, et al.
Publicado: (2022)

Arsenic trioxide as an inducer of immunogenic cell death
por: Kepp, Oliver, et al.
Publicado: (2023)

Immunological consequences of arsenic trioxide-induced necrosis
por: Gavali, Shubhangi, et al.
Publicado: (2023)

Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-125b is involved in the anti-migration/invasion effects of arsenic trioxide on human chondrosarcoma
por: Bao, Xing, et al.
Publicado: (2016)

Role for Fgr and Numb in retinoic acid-induced differentiation and G0 arrest of non-APL AML cells
por: Kazim, Noor, et al.
Publicado: (2021)

Retracted: Evidences of Protective Potentials of Microdoses of Ultra-High Diluted Arsenic Trioxide in Mice Receiving Repeated Injections of Arsenic Trioxide
por: Medicine, Evidence-Based Complementary and Alternative
Publicado: (2021)

Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2
por: Jambrovics, Károly, et al.
Publicado: (2020)

APL2 in depth
por: Thomson, Norman D, et al.
Publicado: (1995)

APL 76 Conference
por: Hunter, G Truman
Publicado: (1976)

International Conference on APL
por: Van der Linden, Gijsbert
Publicado: (1980)

Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial
por: Zhang, Li, et al.
Publicado: (2018)

Sequential Treatment of Arsenic Trioxide Followed by All Trans Retinoic Acid with Anthracyclines has Excellent Long-Term Cure in Acute Promyelocytic Leukemia
por: Devadas, Santhosh Kumar, et al.
Publicado: (2020)

Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience
por: Autore, Francesco, et al.
Publicado: (2021)

An in vivo genome‐wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer
por: Sultan, Mohammad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nnvu0v6u28508pokvfk8m9f5na